枸櫞酸他莫昔芬

價格	詢價
包裝	25Kg/Drum

最小起訂量	25Kg
發(fā)貨地	湖北
更新日期	2020-11-10

產(chǎn)品詳情

中文名稱:枸櫞酸他莫昔芬	英文名稱:Tamoxifen Citrate
CAS:54965-24-1	產(chǎn)品類別: boshan

TaMoxifen citrate
CAS：54965-24-1

Tamoxifen Citrate is a potent and selective inhibitor of PKC (protein kinase C). It is known that Tamoxifen Citrate functions in PKC ε translocation. Studies suggest that Tamoxifen Citrate functions as an estrogen receptor antagonist in breast tissue. Once bound to the estrogen receptor Tamoxifen Citrate will not allow any other ligand to bind to the receptor. In contrast, Tamoxifen Citrate is an agonist towards this receptor in tissues of the endometrium. Studies indicate Tamoxifen Citrate inhibits DNA synthesis and transcription by recruiting co-repressors, which stop estrogen from interacting with genes. When combined with PAX2, Tamoxifen Citrate can inhibit the proliferation of ERBB2. It is also a high affinity activator of the GPR30 receptor. Tamoxifen Citrate is an activator of Estrogen Receptor.

Common Name	Tamoxifen citrate
CAS Number	54965-24-1	Molecular Weight	563.638
Density	N/A	Boiling Point	665.9ºC at 760 mmHg
Molecular Formula	C32H37NO8	Melting Point	140-144 °C
MSDS	ChineseUSA	Flash Point	356.5ºC
Symbol	GHS07, GHS08	Signal Word	Danger

Description	Tamoxifen Citrate is a selective estrogen receptor modulator (SERM).
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Cancer
Target	Estrogen receptor[1]
In Vitro	Tamoxifen shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2].
In Vivo	The Tamoxifen-inducible gene knockout strategy has clear advantages in that expression of a gene can be ablated in adult mice at will in a tissue specific manner. To study the role of Med1 in adult heart, 7-week old TmcsMed1-/- mice are given a daily Iintraperitoneal injection of Tamoxifen at a dose of 65 mg/kg for 5 days and killed at selected intervals thereafter. qPCR analysis of RNA shows that the Med1 expression begin to decrease after 3 days of Tamoxifen injection (about 70% decrease), and by 5 days of injection, Med1 expression is almost non-detectable in the heart. Tamoxifen-inducible cardiac-specific disruption of Med1 (TmcsMed1-/-) in adult mice causes dilated cardiomyopathy[3].
Animal Admin	Mice[3] Seven-week old TmcsMed1-/- mice and the wild-type littermates are then administered Tamoxifen intraperitoneally at a daily dose of 65 mg/kg body weight for 5 days and then killed at selected intervals after initiation of Tamoxifen treatment. For each experiment 3 to 5 mice for control and csMed1-/- are used. To obtain survival curve 41 csMed1-/- and 41 csMed1fl/fl mice are used. Thirteen TmcsMed-/- mice and the same number of littermates are used for the survival curve experiments using Tamoxifen inducible model. The specific criteria for animal euthanasia included absence of food or water intake, slow or no mobility, weak or absence of heart beat, absence of palpitation of the chest as well as absence of respiratory movement. Mice are euthanized by intraperitoneal pentobarbital injection at the dose of 150mg/kg body weight to minimize suffering.
References	[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755.

Boiling Point	665.9ºC at 760 mmHg
Melting Point	140-144 °C
Molecular Formula	C32H37NO8
Molecular Weight	563.638
Flash Point	356.5ºC
Exact Mass	563.251892
PSA	144.60000
LogP	4.74760
Storage condition	2-8°C
Water Solubility	slightly soluble

CONTACT :

Tel & WhatsApp : +86 15972591113

QQ & WeChat: 577507723

Skype : smile491012

關(guān)鍵字： Tamoxifen Citrate;Tamoxifen;

公司簡介

九州通是一家以西藥、中藥、器械為主要經(jīng)營產(chǎn)品，以醫(yī)療機構(gòu)、批發(fā)企業(yè)、零售藥店為主要客戶對象，并為客戶提供信息、物流等各項增值服務(wù)的大型企業(yè)集團。公司立足于醫(yī)藥健康行業(yè)，是中國醫(yī)藥商業(yè)領(lǐng)域具有全國性網(wǎng)絡(luò)的少數(shù)幾家企業(yè)之一，于2010年11月2日在上海證券交易所掛牌上市（股票簡稱：九州通，證券代碼：600998），公司連續(xù)多年位列中國醫(yī)藥商業(yè)企業(yè)第四位，領(lǐng)跑中國民營醫(yī)藥商業(yè)企業(yè)，2020年位列《財富》（中文版）500強第100位。九州通成立于1999年3月，總部位于湖北省武漢市。截止2020年9月30日，公司注冊資本18.78億元，總資產(chǎn)787.17億元。實現(xiàn)營業(yè)收入803.20億元，凈利潤21.41億元，分別較上年同期增長9.46%和110.23％?？鄢墙?jīng)常性損益后歸屬于上市公司股東的凈利潤為12.52億元，較上年同期增長45.12%。2019年公司實現(xiàn)營業(yè)收入994.97億元，歸屬于上市公司股東的凈利潤17.81億元，分別較上年同期增長14.19%和28.96%。員工兩萬五千余人。直營和加盟零售連鎖藥店1074家。

成立日期	1999-03-09 （26年）	注冊資本	1877663513
員工人數(shù)	500人以上	年營業(yè)額	￥ 1億以上
主營行業(yè)	醫(yī)藥中間體,原料藥,獸藥原料,維生素類	經(jīng)營模式	貿(mào)易,工廠

九州通醫(yī)藥集團股份有限公司

非會員

公司成立：26年
注冊資本：1877663513
企業(yè)類型：私營
主營產(chǎn)品：枸櫞酸他莫昔芬克霉唑奮乃靜硝酸異山梨酯鹽酸美西律托吡卡胺
公司地址：號漢陽區(qū)龍陽大道特

進入店鋪

詢盤

店內(nèi)推薦

克霉唑

詢價

奮乃靜

詢價

硝酸異山梨酯

詢價